ALPS Medical Breakthroughs ETF (SBIO)
|Ex-Dividend Date||Dec 19, 2019|
|Day's Range||45.24 - 46.24|
|Inception Date||Dec 31, 2014|
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Top 10 Holdings28.52% of assets
|Dec 19, 2019||$0.01585||Dec 27, 2019|
|Dec 20, 2018||$0.78406||Dec 27, 2018|
|Dec 21, 2017||$0.57949||Dec 28, 2017|
Sector ETF report for SBIO
Wall Street ended on a negative note last week just the week before that, strengthening the worth of the adage that September is historically the worst month of the year for stocks.
The issue of pharmaceuticals pricing reform — a long-time favorite discussion on Capitol Hill — is gaining momentum, and some healthcare assets are bearing that burden. For example, the ALPS Medical Bre...
This year hasn't been kind to biotechnology stocks and related exchange traded funds. The headwinds faced by these assets were ratcheted up last week when the Biden administration revealed plans to purs...
Large-cap biotechnology stocks finally have some momentum, but relative to the broader healthcare sector, biotech is a 2021 laggard. The situation is worse for smaller biotech stocks and the related exc...
Sector ETF report for SBIO
Industry analysts continue to posit that biotechnology consolidation is poised to accelerate through year-end – a scenario that could propel the ALPS Medical Breakthroughs ETF (SBIO) further forward. Wh...
Biotechnology has long been fertile territory for disruptive growth and innovation in the healthcare sector. The ALPS Medical Breakthroughs ETF (SBIO) is one of the premier exchange traded funds to tap...
Experienced investors know that talk of mergers and acquisitions activity is a near constant in the healthcare industry. Due to the sluggish pace of deal-making last year owing to the onset of the coron...
We have presented five ETFs from different sectors that have easily crushed the Russell 2000 Index over the past month.
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
Biotechnology equities are slumping to start 2021, with the S&P Biotechnology Select Industry Index down 10% year-to-date. Mergers and acquisitions activity, which are typically vibrant in the biotech s...
Biotechnology sector-related exchange traded funds could stumble in the near-term as increased regulatory scrutiny weighs on drugmakers. Among the hardest hit areas of Tuesday, the ALPS Medical Breakthr...
We have presented five ETFs that are easily crushing the Russell 2000 Index this year and are likely to continue their strong performance at least in the near term.
Already off to a strong start in 2021, the ALPS Medical Breakthroughs ETF (SBIO) extended the good vibes by jumping 9% in the first full trading week of February. SBIO focuses on small- and mid-cap comp...
Clinical trials are of the utmost importance to biotechnology investors, but not all exchange traded funds adequately address the phenomenon. The ALPS Medical Breakthroughs ETF (SBIO) takes a different ...
Large cap biotechnology companies are flush with cash, and they're on the prowl for takeover targets, a scenario that could bode well for the ALPS Medical Breakthroughs ETF (SBIO). SBIO focuses on small...
After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded fun...